WASHINGTON,
Feb. 6, 2017/PRNewswire/ -- At the SLAS 2017
International Conference & Exhibition(www.slas2017.org),
Brukertoday announced its newMALDI PharmaPulse 2.0solution (MPP 2.0), which significantly enhances the automation capabilities of therapifleXMALDI-TOF mass spectrometer, with its proprietary scanning 10 kHz solid-state laser technology, for label-free, uHTS assays in pharmaceutical drug discovery.MPP 2.0enables pharma scientists to automate MALDI methods development to screen millions of compound chemical libraries using 384, 1536, 3072 or 6144-well microtiter format MALDI sample plates.
The newMALDI PharmaPulse 2.0solution can measure up to 10 different samples per second, a 100- to 1000-fold increase in speed and throughput for mass spectrometry-based, label-free screening. TheMPP 2.0solution is compatible with the latest 1536 simultaneous liquid spotters, and fully integrated automation solutions for uHTS, e.g. by HighRes Biosolutions (www.highresbio.com), or others.
TheMPP 2.0solution incorporates an
Assay Developmentmodule and a Screening module. The Assay Development module harnesses the speed of therapifleXMALDI PharmaPulse在一个多维的方法中,执行序列dilutions, mixing different buffer concentrations and other assay components and uses a proprietary algorithm to identify the optimum assay conditions. The Screening module synchronizes with external lab automation protocols to seamlessly integrate with the symphony of robotics required to perform fully automatic, ultra-high speed screening campaigns.
The GSK (
GlaxoSmithKline plc,
UK) Platform Technology and Science group will present data at SLAS 2017 (Haslam et al. Poster 1194, Tuesday
1-3 pm). The Poster shows the application of rapifleXMALDI PharmaPulse2.0 coupled with a nanoliter 1536 simultaneous pipettor (CyBio®Well vario,
Analytik Jena)中d analysis of low volume, 1536-well enzyme assays. The GSK work demonstrates an automated workflow that enables sample plate preparation and analysis in just 8-10 minutes. The workflow illustrates the advantages of label-free mass spectrometry (MS) detection when coupled with the kind of ultra-high throughput that is typically associated with fluorescence-based detection. The data clearly shows the potential for true high throughput screening by MS.
Dr.
Meike Hamester, Director of the Pharmaceutical Business Unit at Bruker Daltonics, commented: "The newMALDI PharmaPulse 2.0user interface was developed in cooperation with scientists for seamless integration of mass spectrometry with uHTS robotics routinely used in the pharmaceutical industry. The unambiguous nature of direct mass measurement for primary screens, the enormous cost savings with label-free detection and just nanoliter sample consumption, coupled to smart software, significantly enhances the utility of theMALDI PharmaPulse 2.0solution."
She continued: "We were very pleased with several keyMPP 2.0orders from major pharma companies on both sides of the Atlantic in the fourth quarter of 2016, and we believe that theMPP 2.0solution will become a commercial success in 2017 and beyond. First installations of the newrapifleX MALDI PharmaPulse 2.0at Boehringer Ingelheim in Biberach,
Germanyand at Genentech in
San Francisco, CA(USA) were already successfully completed in late 2016."
教授
Matthias Trostat
The Institute for Celland
Molecular Bioscience (ICaMB) of Newcastle University,
UK, stated: "The novel laser technology, digitizer and generally improved instrument performance of therapifleXmassively increases speed and signal-to-noise compared to previous instruments. These features make it the instrument of choice for high-throughput MALDI-TOF mass spectrometry in drug discovery."
To learn more, please attend the SLAS 2017 Technical Seminar on
Tuesday, February 7th, 2017from 9:30–10:15 am ET in Room 151A of the
Walter E. Washington Convention Centerfor an informative tutorial on High-Throughput Screening presented by
Melanie Leveridge, the Director, Screening Profiling and Mechanistic Biology, at the
GSK Medicines Research Centrein
Stevenage, UK, presenting: 'Further Advancements in MALDI-TOF Mass Spectrometry towards Ultra High Throughput Screening using the
BrukerrapifleX System and 1536 Parallel Pipetting,'and the talk by Swen Tyrasa, Head of Automation at
Analytik Jenain Jena,
Germany: 'Overcome Bottlenecks in MALDI Sample Plate preparation – 1536 Parallel Pipetting – beyond just spotting.'
About therapifleXMALDI Time-of-Flight Mass Spectrometer
TherapifleXMALDI-TOF mass spectrometer is the heart of theMALDI PharmaPulse2.0 solution. It is the only MALDI mass spectrometer with unique and proprietary 10 kHz scanning laser technology and measures up to 10 samples per second. The enhanced sensitivity and exceptional robustness-by-design allow unattended operation during pharma primary screening campaigns. All performance characteristics of therapifleXMALDI TOF and TOF/TOF instruments surpass anything seen before.
About
Bruker Corporation(NASDAQ: BRKR)
For more than 50 years,
Brukerhas enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers,
Brukeris enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visitwww.energie2point0.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bruker-introduces-maldi-pharmapulse-20-solution-at-slas-2017-for-100x-faster-mass-spectrometry-based-label-free-screening-in-drug-discovery-300402229.html
SOURCE
Bruker Corporation